The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
VAXELIS (Maxx Pharma Pty Ltd)
Product name
VAXELIS
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
158 (255 working days)
Active ingredients
DTPa5-HB-IPV-Hib
Registration type
NCE/NBE
Indication
VAXELIS (DTPa5-HB-IPV-Hib) (suspension for injection) is indicated for primary and booster vaccination in infants and toddlers from the age of 6 weeks, against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive diseases caused by Haemophilus influenzae type b (Hib).
The use of VAXELIS should be in accordance with official recommendations.